Phase I Clinical Trial of a Day-1, -3, -5 Every 3 WeeksPhase I Clinical Trial of Day-1, -3, -5 Every 3 Weeks Schedule with Titanocene Dichloride (MKT 5) in Patients with Advanced Cancer. (Phase I Study Group of the AIO of the German Cancer Society)

Publisher： Karger

E-ISSN： 2296-5262|23|6|576-579

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.23, Iss.6, 2001-01, pp. : 576-579

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase I Trial of a 5-Day Schedule of Intravenous Topotecan and Etoposide in Previously Untreated Patients with Small-Cell Lung Cancer

By  

Oncology, Vol. 61, Iss. 1, 2001-09 ,pp. : 25-29

Karger

Access to resources Recommend Favorite

A Phase I Clinical Trial of Topotecan Given Every 2 Weeks in Patients with Refractory Solid Tumors

By  

Oncology, Vol. 61, Iss. 4, 2001-11 ,pp. : 265-270

Karger

Access to resources Recommend Favorite

Oxaliplatin in Combination with Infusional 5-Fluorouracil and Leucovorin Every 2 Weeks as First-Line Treatment in Patients with Advanced Colorectal Cancer: A Phase II Study

By  

Oncology, Vol. 61, Iss. 1, 2001-07 ,pp. : 36-41

Karger

Access to resources Recommend Favorite

Phase II Clinical Trial of Titanocene Dichloride in Patients with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 1, 2000-03 ,pp. : 60-62

Karger

Access to resources Recommend Favorite

A phase 1 clinical trial of sequential pralatrexate followed by a 48‐hour infusion of 5‐fluorouracil given every other week in adult patients with solid tumors

By  

CANCER, Vol. 121, Iss. 21, 2015-11 ,pp. : 3862-3868

John Wiley & Sons Inc

Access to resources Recommend Favorite